---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-26-000033"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:43:32.434727+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed

## Summary
- Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.
- REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.
- Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.
- Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.
- Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16.

## SEC filing metadata
- accession: 0000879407-26-000033
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/0000879407-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/arwr-20260205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-26-000033
- JSON: https://secwatch.observer/filing/0000879407-26-000033.json
- Plain text: https://secwatch.observer/filing/0000879407-26-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.